Cargando…
Keratin 7 expression in hepatic cholestatic diseases
We evaluated keratin 7 (K7) hepatocellular expression in 92 patients with common types of acute and chronic cholestatic diseases caused by bile duct obstruction/destruction or parenchymal lesions [acute hepatitis (n=20), mixed/pure cholestasis (n=16), primary biliary cholangitis-PBC (n=35), primary...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516784/ https://www.ncbi.nlm.nih.gov/pubmed/34312700 http://dx.doi.org/10.1007/s00428-021-03152-z |
_version_ | 1784583868474458112 |
---|---|
author | Sakellariou, S. Michaelides, C. Voulgaris, T. Vlachogiannakos, J. Manesis, E. Tiniakos, D. G. Delladetsima, I. |
author_facet | Sakellariou, S. Michaelides, C. Voulgaris, T. Vlachogiannakos, J. Manesis, E. Tiniakos, D. G. Delladetsima, I. |
author_sort | Sakellariou, S. |
collection | PubMed |
description | We evaluated keratin 7 (K7) hepatocellular expression in 92 patients with common types of acute and chronic cholestatic diseases caused by bile duct obstruction/destruction or parenchymal lesions [acute hepatitis (n=20), mixed/pure cholestasis (n=16), primary biliary cholangitis-PBC (n=35), primary sclerosing cholangitis-PSC (n=10), vanishing bile duct syndrome (n=3), complete large bile duct obstruction due to space-occupying lesions (n=8)]. K7 immunohistochemical hepatocellular expression and ductular reaction (DR) were semi-quantitatively assessed. Results were correlated with liver enzyme serum levels, cholestasis type, histological features, hepatocellular Ki67 labelling index (LI) and HepPar1 expression. Hepatocellular K7 expression was detected in 87% (81/92) cases and in all cholestatic disease types with lowest incidence in pure/mixed cholestasis and highest in incomplete bile duct obstruction (iBDO), reaching 100% in PSC. K7-positive hepatocytes had low Ki67 LI (0-5%) retaining HepPar1 expression, irrespective of disease type. PSC cases had high K7 hepatocellular expression even with intact bile ducts, a feature that may aid differential diagnosis of cholestatic syndromes. K7 hepatocellular expression significantly correlated with cholestasis type, bile duct loss and fibrosis stage. It was higher in milder acute cholestatic hepatitis showing inverse correlation with hepatocyte proliferation and serum transaminase levels. In iBDO, younger age independently correlated with high K7 expression, while serum GGT levels showed a nearly significant correlation. Correlation with DR findings implied that K7-positive hepatocytes may result through metaplasia. In conclusion, K7 hepatocellular expression is a sensitive though non-specific marker of cholestasis. It may represent a cytoprotective reaction of resting hepatocytes in cholestasis of longer duration especially in younger patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00428-021-03152-z. |
format | Online Article Text |
id | pubmed-8516784 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-85167842021-10-29 Keratin 7 expression in hepatic cholestatic diseases Sakellariou, S. Michaelides, C. Voulgaris, T. Vlachogiannakos, J. Manesis, E. Tiniakos, D. G. Delladetsima, I. Virchows Arch Original Article We evaluated keratin 7 (K7) hepatocellular expression in 92 patients with common types of acute and chronic cholestatic diseases caused by bile duct obstruction/destruction or parenchymal lesions [acute hepatitis (n=20), mixed/pure cholestasis (n=16), primary biliary cholangitis-PBC (n=35), primary sclerosing cholangitis-PSC (n=10), vanishing bile duct syndrome (n=3), complete large bile duct obstruction due to space-occupying lesions (n=8)]. K7 immunohistochemical hepatocellular expression and ductular reaction (DR) were semi-quantitatively assessed. Results were correlated with liver enzyme serum levels, cholestasis type, histological features, hepatocellular Ki67 labelling index (LI) and HepPar1 expression. Hepatocellular K7 expression was detected in 87% (81/92) cases and in all cholestatic disease types with lowest incidence in pure/mixed cholestasis and highest in incomplete bile duct obstruction (iBDO), reaching 100% in PSC. K7-positive hepatocytes had low Ki67 LI (0-5%) retaining HepPar1 expression, irrespective of disease type. PSC cases had high K7 hepatocellular expression even with intact bile ducts, a feature that may aid differential diagnosis of cholestatic syndromes. K7 hepatocellular expression significantly correlated with cholestasis type, bile duct loss and fibrosis stage. It was higher in milder acute cholestatic hepatitis showing inverse correlation with hepatocyte proliferation and serum transaminase levels. In iBDO, younger age independently correlated with high K7 expression, while serum GGT levels showed a nearly significant correlation. Correlation with DR findings implied that K7-positive hepatocytes may result through metaplasia. In conclusion, K7 hepatocellular expression is a sensitive though non-specific marker of cholestasis. It may represent a cytoprotective reaction of resting hepatocytes in cholestasis of longer duration especially in younger patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00428-021-03152-z. Springer Berlin Heidelberg 2021-07-27 2021 /pmc/articles/PMC8516784/ /pubmed/34312700 http://dx.doi.org/10.1007/s00428-021-03152-z Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Sakellariou, S. Michaelides, C. Voulgaris, T. Vlachogiannakos, J. Manesis, E. Tiniakos, D. G. Delladetsima, I. Keratin 7 expression in hepatic cholestatic diseases |
title | Keratin 7 expression in hepatic cholestatic diseases |
title_full | Keratin 7 expression in hepatic cholestatic diseases |
title_fullStr | Keratin 7 expression in hepatic cholestatic diseases |
title_full_unstemmed | Keratin 7 expression in hepatic cholestatic diseases |
title_short | Keratin 7 expression in hepatic cholestatic diseases |
title_sort | keratin 7 expression in hepatic cholestatic diseases |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516784/ https://www.ncbi.nlm.nih.gov/pubmed/34312700 http://dx.doi.org/10.1007/s00428-021-03152-z |
work_keys_str_mv | AT sakellarious keratin7expressioninhepaticcholestaticdiseases AT michaelidesc keratin7expressioninhepaticcholestaticdiseases AT voulgarist keratin7expressioninhepaticcholestaticdiseases AT vlachogiannakosj keratin7expressioninhepaticcholestaticdiseases AT manesise keratin7expressioninhepaticcholestaticdiseases AT tiniakosdg keratin7expressioninhepaticcholestaticdiseases AT delladetsimai keratin7expressioninhepaticcholestaticdiseases |